Precision Biosciences Inc DTIL

$7.57 -0.47 (-5.91%)

Valuation

Market cap
211,336,000
Revenue TTM
$34,260,000
Net income TTM
$-45,720,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
-133.45%
Debt to equity
0.50

Trading

Volume
394,600
Avg volume
330,082
Day's range
$7.52 – $8.16
Shares out
27,936,000
Stochastic %K
20%
Beta
1.34
Analysts
Strong Buy
Price target
$29.40

Price

Company profile

Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DN...

Show more

Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits, as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; and PBGENE-DMD (Excision) for the treatment of Duchenne muscular dystrophy. In addition, the company develops PBGENE-3243 for the treatment of m.3243 associated mitochondrial diseases; and iECURE-OTC (Insertion) for ornithine transcarbamylase deficiency. It has collaboration agreements with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azercabtagene zapreleucel for autoimmune diseases and other indications; and iECURE, Inc., an ARCUS-mediated targeted gene insertion. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Industry
Biotechnology
Sector
Healthcare
Phone
919 314 5512
Website
https://precisionbiosciences.com
Address
302 East Pettigrew St., Suite A-100, Durham, United States

Latest news

Stocktwits

History101 Nov 12, 3:24 PM
$DTIL someone a week ago said this would drift down into the 8s and he was spot on
2 replies
chungana Nov 12, 3:22 PM
$DTIL Very excited about DMD results at end of year, too…🥳
0 replies
chungana Nov 12, 2:46 PM
$DTIL Hardly any daily volume in this stock, bcuz very, very few sellers!$ Everyone with a brain knows what’s coming in 2027!$ Wait until some more amazing data gets reported in the weeks and months ahead!$ 🤑
0 replies
chungana Nov 12, 2:22 PM
$DTIL Looks like the buyers of rexent offering are going to give us some more cheapies in the days ahead!$ 🥳
0 replies
chungana Nov 12, 2:03 PM
$DTIL Load the boat!$ DTIL going to be maybe biggest winner of 2027, imho!$ 🤗🤑🤗
0 replies
chungana Nov 11, 2:17 PM
$DTIL It will be really interesting to see what happens to share price if a P1 patient agrees to end NUC therapy and shows lasting undetectable pgRNA/viral DNA!$ 🥳
0 replies
chungana Nov 11, 1:50 PM
$DTIL A bit strange—hardly anyone knows about this company and what they are on the cusp of accomplishing…amazing!$ Come June, 2027, I think that is going to change for good once interim data is reported!$ This current share price is going to look infinitesimally small by end of next year, imho!$ 🤩
0 replies
Merlintrader Nov 10, 8:11 PM
$DTIL Precision BioSciences (DTIL): cash $108M, runway through 2028 Free weekly catalyst newsletter: https://merlintrader.beehiiv.com/p/week-ahead-10-catalysts-we-re-watching-november-9-13 Not investment advice.
0 replies